Genzyme Canada HomeGenzyme Corporate HomeSearchContact UsGenzyme Websites
Corporate InfoOur Therapies and Products
English  |  Français

Health Care Professionals and Patients:
Research our treatment areas and services for your medical condition and health care practice More >
  Learn about our Canadian operations.  
  Explore opportunities in our entrepreneurial culture.  
  Find out about what is new in our research and development.  
  View a calendar of our events.  
  See what's new for Genzyme in Canada.  


First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada
Mississauga, ON - Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. More>

Health Canada Approves Genzyme’s AUBAGIOŽ (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis
Mississauga, ON - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIOŽ (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. More>

Join Genzyme in the upcoming Walk to End MS
Lace up your shoes and join Genzyme Canada as we partner with the MS Society in their annual Walk to End MS. This year Genzyme is participating as the Presenting Sponsor for the Quebec walk and a Provincial Sponsor for the Ontario walk. 55 communities in Ontario will be lacing up on April 27th, May 4th or May 25th and 21 communities in Quebec on May 25th. We invite you to be part of the Genzyme team(s) as we accept the challenge that MS brings to thousands of Canadians. Every Step Matters. More>


Subscribe | Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2014 Genzyme, a Sanofi company. All rights reserved.